Drug Trial Radar · NCT07743541
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Sep 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with recurrent or progressive uterine endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor therapy. The primary objectives of Phase 1 of this study are to determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). The primary objective of Phase 2 of this study is to evaluate the efficacy of TUB-040 monotherapy at the RP2D in endometrial cancer.
Conditions
- Uterine Endometrial Cancer
Interventions
TUB-040 - Dose escalationDrug
TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle.
TUB-040 - RP2DDrug
TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle. Dose based on the RP2D
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years
- Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to 3 years
- Phase 2: Overall Response Rate (ORR)Time frame: Up to 3 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
START Los Angeles
Los Angeles, California
START New Jersey
East Brunswick, New Jersey
START New York-Long Island
Lake Success, New York
START Mountain Region, LLC
West Valley City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.